Anti-marijuana quack Dave Weldon to take over CDC

Few major hospitals receiving Dave Weldon’s job resume would hire him. Few patients would trust him as their doctor. Yet, if confirmed, former congressional representative and physician Dr. David Weldon (R-Fla.) will head the U.S. Centers for Disease Control and Prevention (CDC), becoming the overlord of a government agency whose function is to protect people from pandemics and other illnesses.

Weldon has some hang-ups regarding marijuana, along with several other things. He sees cannabinoids as medically ineffective. He said marijuana’s medical use is a form of “lunacy”. He is anti-abortion. He is an anti-vaxxer. Contrary to established medical science he believes thimerosal used as a preservative in vaccines leads to autism. Ironically, marijuana has recently shown promise in reducing symptoms of autism. Weldon rejects therapies that successfully treat certain cancers and disorders of the blood and the immune system because the treatments employ human stem cells. Stem cells have the potential to assist in the treatment of diabetes, Parkinson’s disease, heart disease, Alzheimer’s, and spinal cord injuries, unless research funding is cut off.

After he left Congress, Dr. Weldon returned to his medical practice and continued to be involved in community and faith-based initiatives. His elevation to a possible CDC directorship hinges entirely on his close association with a politically styled religious group calling itself the New Apostolic Reformation (NAR). The NAR was founded in the 1990s. Some of its members are Pentecostalists who believe in faith healing. Firebrand prosperity-gospel preacher Paula White is a charismatic evangelical pastor associated with the NAR. As President-elect Donald Trump’s current spiritual advisor or guru, White has a Rasputin-like influence over Trump. She boasts she will bring in angelic reinforcements to outlaw democracy and create an American theocracy. Anti-marijuana prohibitionist and Florida Attorney General Pam Bondi, Trump’s pick for U.S. Attorney General, is tied to the NAR. So is Ann Coulter. Other NAR notables include Lauren Boebert, a supporter of marijuana for medical use only, and Georgia Congresswoman Marjorie Taylor Greene who believes marijuana smokers are “zombies”.

True believers in marijuana’s satanic powers are right about one thing. Despite all angelic reinforcements to the contrary, marijuana, the Devil’s Lettuce, is capable of changing people’s minds about myths and fallacies. The plant achieves this miracle by generating faith-based laws that lead to prohibitionists vilifying themselves and ultimately their ideologies by their support of marijuana drug enforcement, or employment within its ranks. Not all conservatives fall into the trap.

In the early 1970s conservative commentator William F. Buckley positioned himself and his sailboat on the high seas outside the three-mile limit of U.S. legal authority and tried marijuana for the first time. Buckley’s one and only cannabis experience was much ado about nothing: “…it didn’t do a thing for me.” Nor did it do him any harm, like getting him arrested. A conservative is commonly characterized as being a stick-in-the-mud, however Buckley quickly changed his mind about marijuana and went on to publicly advocate for its decriminalization.

This entry was posted in Servetus. Bookmark the permalink.

6 Responses to Anti-marijuana quack Dave Weldon to take over CDC

  1. If you thought Bondi and Weldon are bad, I know plenty of Louisiana politicians in both parties who are even worse:
    -Laurie Schlegel (R-Metairie)
    -Beth Mizell (R-Franklinton)
    -Heather Cloud (R-Turkey Creek)
    -John Milkovich (D-Shreveport, also a known anti-Vaxxer)
    -Danny McCormick (D-Oil City)
    -Katrina Jones (D-Monroe)
    -John Bel Edwards (Former Democrat governor)
    -Sharon Hewitt (R-Slidell)
    -Lance Harris (R-Alexandria, also known as the dipshit behind our unconstitutional Blue Lives Matter law.)
    -Kellee Dickerson (Moron Republican who tried to outlaw joining the American Library Association.)
    -Kathy Edmonston (R-Kenner, and another anti-vaxxer.)
    -Lauren Ventrella (One of the co-authors of our equally unconstitutional Ten Commandments bill.)
    This isn’t getting into local politicians, church leaders, prosecutors (E. G. Hugo Holland), and sheriffs.

    • John Doe says:

      I strongly disagree with Servetus’ statement about Dave Weldon. His views on marijuana are not only outdated but also harmful to the progress we’ve made in drug policy reform.

  2. Servetus says:

    Brain volume changes seen in opioid users:

    10-Dec-2024 — OAK BROOK, Ill. – Researchers at the Yale School of Medicine found structural and functional alterations in specific brain regions of individuals with opioid use disorder. The study’s results were published today in Radiology, a journal of the Radiological Society of North America (RSNA). […]

    In the study, Dr. Mehta and colleagues conducted a secondary analysis of data from the National Institutes of Health-funded Collaboration Linking Opioid Use Disorder and Sleep Study (CLOUDS), comparing participants with opioid use disorder on methadone treatment and healthy controls. The data included structural MRI and functional MRI (fMRI) exams performed between February 2021 and May 2023.

    Resting state fMRI allows researchers to measure brain activity by detecting changes in blood flow. With resting state fMRI, the connectivity between neural regions—known as resting state networks—can be observed while the brain is at rest. […]

    Whole-brain analysis revealed structural and functional alterations in opioid receptor-dense regions in the opioid use disorder group compared to healthy controls. In individuals with opioid use disorder, the thalamus and right medial temporal lobe of the brain were smaller in volume, while the cerebellum and brainstem were larger in volume than in controls. In the individuals with opioid use disorder, all these brain regions also had increased functional connectivity compared to controls.

    “We observed widespread increases in global connectivity in individuals with opioid use disorder,” Dr. Mehta said. “Our goal is to understand better what could have caused these alterations to inform new treatment targets.”

    The results also revealed that women in the group with opioid use disorder had smaller medial prefrontal cortex volume, compared to males in the same group. […]

    Dr. Mehta said the study builds a foundation for future research to investigate potential behavioral implications of these brain differences and whether they are permanent.

    “Our eventual goal is to examine how brain alterations in individuals with opioid use disorder may be linked to outcome measures,” she said. […]

    AAAS Public Science News Release: Brain volume changes seen in opioid users

    Radiology: Alterations in Volume and Intrinsic Resting-State Functional Connectivity Detected at Brain MRI in Individuals with Opioid Use Disorder

    Authors: Collaborating with Dr. Mehta were Hannah Peterson, B.S., Jean Ye, B.A., Ahmad Ibrahim, M.B.B.S., Gul Saeed, M.B.B.S., Sarah Linsky, M.P.H., Iouri Kreinin, C.C.R.P., C.C.R.C., Sui Tsang, M.S., Uzoji Nwanaji-Enwerem, Ph.D., F.N.P.-B.C., Anthony Raso, M.H.S., Jagriti Arora, M.S., Fuyuze Tokoglu, M.S., Sarah W. Yip, Ph.D., C. Alice Hahn, B.A., Cheryl Lacadie, B.S., Abigail S. Green, M.D., Ph.D., Sangchoon Jeon, Ph.D., R. Todd Constable, Ph.D., Declan T. Barry, Ph.D., Nancy S. Redeker, R.N., M.S.N., Ph.D., Henry Yaggi, M.D., M.P.H., and Dustin Scheinost, Ph.D.

  3. Servetus says:

    Canadian cannabis researchers are complaining that research funding for marijuana research is being sponsored by for-profit industries instead of the Canadian government:

    19-Dec-2024 – (Toronto, Canada) – In the first study of its kind, research led by the Centre for Addiction and Mental Health (CAMH) sheds light on the ethical complexities and systemic barriers facing scientists conducting cannabis research funded by the for-profit cannabis industry.

    Recently published in the journal Social Science & Medicine, the qualitative study titled Canadian cannabis researcher perspectives on the conduct and sponsorship of scientific research by the for-profit cannabis industry reveals that while researchers are driven by a commitment to public health and high-quality research, systemic barriers often force them to rely on industry partnerships. Researchers adopt personal strategies—such as prioritizing transparency, aligning values, and maintaining independence—to navigate these relationships. However, the study emphasizes that these challenges reflect structural issues that require systemic, rather than individual, solutions. […]

    The study involved 38 semi-structured interviews with a diverse group of academic researchers, peer researchers, and clinicians across all Canadian provinces. Participants were recruited through professional networks, email invitations, and snowball sampling, ensuring a wide range of perspectives across age, gender, geography, and racial and ethnic identities. Thematic analysis of the interviews provided a comprehensive understanding of the ethical and practical challenges posed by industry sponsorship in cannabis research.

    Key recommendations in the study include increasing public funding for cannabis research to reduce reliance on industry sponsorship, enhancing transparency about industry relationships, and ensuring that research agendas are not unduly influenced by industry interests. The study also suggests implementing institutional policies that promote independence and integrity in research, such as clear guidelines for managing conflicts of interest and fostering collaborations that align with public health goals. These measures aim to safeguard the integrity of cannabis research and ensure it benefits public health.

    This work builds on previous research by Buchman’s team investigating industry partnerships in cannabis studies. A 2023 paper, Cannabis companies and the sponsorship of scientific research: A cross-sectional Canadian case study, found that for-profit cannabis companies have been sponsoring, financially and non-financially, cannabis research since the legalization of recreational cannabis in Canada in 2018. The study highlighted concerns about the “funding effect,” where industry sponsorship could lead to biased, sponsor-favorable outcomes. It underscored the need for greater understanding of Canada’s regulatory environment, which often necessitates researcher-industry collaboration for certain cannabis studies.

    Dr. Klara Vichnevetski, Director of the CAMH Technology Transfer and Industry Partnerships Office, who was not involved in this study, added: “As the cannabis research landscape evolves, this study underscores the importance of fostering transparent and ethical industry collaborations. By addressing potential biases in industry-sponsored research, we can build responsible partnerships that uphold high-quality, impactful research while maintaining academic integrity and public trust.” […]

    AAAS Public Science News Release: New study highlights ethical challenges in conducting cannabis research in Canada — CAMH-led research reveals systemic barriers and ethical considerations in industry-funded cannabis research in Canada

    Social Science and Medicine: Canadian cannabis researcher perspectives on the conduct and sponsorship of scientific research by the for-profit cannabis industry

    Authors: Daniel Z. Buchman, Brooke Magel, Rowen Shier, Titilayo Esther Davies, Abhimanyu Sud, Shreya Mahajan, Roberta K. Timothy, Sophie Soklaridis, Quinn Grundy.

  4. Servetus says:

    A study from Emory University details modern attitudes toward professional psychedelic therapy:

    ATLANTA, Georgia, USA, 17 December 2024 – …from Emory University, a new study published today reveals complex attitudes toward psychedelic therapy, with detailed statistics showing both strong support for potential benefits and significant awareness of risks.

    The research…surveyed 178 attendees at an academic conference focused on psychedelics and spiritual care. Among participants, 32 were active psychedelic therapy facilitators, of whom 87.5% reported prior personal experience with psychedelics and 62.1% had used psychedelics specifically for therapeutic purposes.

    “What struck us most was the sophisticated understanding of both benefits and risks among attendees of the conference as well as psychedelic care practitioners,” says Professor Roman Palitsky from Emory University’s Department of Psychiatry and Behavioral Sciences, the study’s corresponding author. “While 40.2% of participants agreed that psychedelics could be harmful even in therapeutic contexts, we also found strong belief in their potential benefits, particularly for specific conditions,” added Dr. Zachary Bosshardt, lead author of the study. […]

    “Among facilitators, we found a preference for established therapeutic frameworks, with 65.6% utilizing supportive or Rogerian psychotherapy, and many others utilizing structured approaches likes cognitive behavioral therapy (CBT). This suggests a bridge between traditional therapeutic approaches and psychedelic treatment.”

    “These findings tell us something important about the evolving landscape of psychedelic therapy,” notes Dr. Boadie W. Dunlop, another study co-author. “We’re seeing a field that’s maturing beyond simple enthusiasm to develop a more nuanced understanding of both opportunities and challenges.” […]

    “The fact that 30.7% of respondents answered ‘not sure’ about potential harmful effects suggests an appropriate level of professional humility about these powerful compounds. This uncertainty might actually be healthy for the field’s development.”

    The research also highlighted important questions about the future of psychedelic therapy, particularly regarding training protocols and the integration of traditional practices with modern medical approaches. […]

    “Our findings suggest we need to develop robust safety protocols while maintaining optimism about therapeutic potential. The high rate of personal psychedelic use among facilitators – 87.5% for any use and 62.1% for therapeutic purposes – also raises important questions about training and preparation for practitioners.” […]

    AAAS Public Science News Release: Attitudes toward psychedelic therapy reveal both promise and caution, new study finds–psychedelic care facilitators express optimism about benefits while maintaining awareness of potential risks

    Genomics Press: Psychedelics: Reading the crowd: attitudes toward psychedelics and psychedelic therapies among attendees at a conference

  5. Servetus says:

    Insights are achieved in treating behavioral disorders by focusing on the tetrapartite synapse of the brain:

    17-Dec-2024 — …neuroscientist Dr. Peter Kalivas reveals crucial insights into how brain circuits drive addictive behaviors and discusses potential new drug targets for treating behavioral disorders. [..]

    …pioneering work on the tetrapartite synapse – a complex cellular structure … includes neurons, astroglia, and the extracellular matrix … has revolutionized how we conceptualize addiction treatment by identifying novel therapeutic targets beyond traditional neurotransmitter systems. […]

    “By taking multiple traits together and clustering them into resilient and vulnerable subpopulations, we are isolating genetic and transcriptomic traits that may contribute to substance use disorders in humans,” Dr. Kalivas notes, highlighting the potential clinical applications of this research. […]

    AAAS Public Science News Release: Addiction neuroscience leader reveals how brain circuits drive behavioral disorders–distinguished neuroscientist Dr. Peter Kalivas shares insights on tetrapartite synapse research

    Genomic Press: Peter W. Kalivas: To the tetrapartite synapse and beyond – A pathway for new drug targets to treat behavioral disorders

Leave a Reply

Your email address will not be published. Required fields are marked *